RegCell, an Emeryville, CA-based biotechnology company developing therapies for autoimmune diseases and transplantation, raised $45.8M in funding.
The round consisted of $8.5M in Seed funding led by The University of Tokyo Edge Capital Partners (UTEC) and Fast Track Initiative (FTI), with participation from Celadon Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital (OUVC), and Kyoto University Innovation Capital (Kyoto i-Cap) and $37.3M in non-dilutive funding (¥5.6 Billion) from Japan’s Agency for Medical Research and Development (AMED).
The company intends to use the funds for the development of its epigenetic reprogramming platform through clinical proof-of-concept to further validate the technology.
Led by CEO Dr. Michael McCullar, RegCell is a global biotechnology company developing cell therapies for autoimmune diseases and transplantation. Its platform addresses unknown or multiple pathogenic antigens with its epigenetic reprogramming technology that simplifies manufacturing, enhances safety, and enables scalable production, bringing cell therapies to a broad spectrum of autoimmune patients, including those with diseases driven by undefined autoantigens.
FinSMEs
18/03/2025